Several clinical trials of checkpoint inhibitors in pretreated NSCLC have shown superior OS versus chemotherapy, with a positive correlation between the expression of PD-L1 and the efficacy of immunotherapy being observed. This evidence concerns the gene CD274 and non-small cell lung carcinoma.